Unlike traditional fiber-based oxygenators, the system is designed to maintain a more natural blood flow, potentially reducing harmful effects on blood components.


RT’s Three Key Takeaways:

  1. Modular Design in Development: Inspira Technologies is developing a modular blood oxygenation delivery system aimed at enhancing oxygen levels and carbon dioxide removal without requiring ventilators.
  2. Potential for Reduced Blood Damage: Unlike traditional fiber-based oxygenators, the system is designed to support a more natural blood flow, potentially minimizing damage to blood components.
  3. Regulatory Approvals for Related Systems: Inspira’s related Inspira Art100 system has received FDA 510(k) clearance and Israeli AMAR certification for cardiopulmonary bypass procedures.

Inspira Technologies OXY BHN Ltd announced the development of a modular configuration for its Vortx blood oxygenation delivery technology, aiming to advance the field of extracorporeal oxygenation and improve critical care practices.

The modular configuration of the Vortx blood oxygenation delivery system is expected to extend the Inspira Art’s range of blood oxygen enrichment and carbon dioxide removal, potentially expanding the versatility of the Inspira Art. The flagship Inspira Art system is being designed to elevate and stabilize declining oxygen saturation levels in patients while they are awake and without a ventilator.

Unlike traditional fiber-based oxygenators, the Vortx is designed to maintain a more natural blood flow, potentially reducing harmful effects on blood components. This technology is protected by 32 patent claims.

[RELATED: Johns Hopkins to Lead $18M Effort to Develop Portable ECMO System]

Inspira continues to develop and refine the modular Vortx blood oxygenation delivery technology, which is expected to enhance the versatility and applicability of the Vortx technology across various medical scenarios.

In May and July 2024, respectively, the company’s Inspira Art100 system obtained US Food and Drug Administration 510(k) clearance for use in CBP procedures, along with the Israeli AMAR certification for both extracorporeal membrane oxygenation and cardiopulmonary bypass procedures.

The company’s other products and technologies, including the Inspira Art also known as the Inspira Art500 or Gen 2, the Inspira Cardi-ART portable modular device, Vortx Oxygen Delivery System, and HYLA blood sensor, are currently being designed and developed and have not yet been tested or used in humans nor approved by any regulatory entity.

ID 348278066 © Vitaliy But | Dreamstime.com